SEC Stock Data Quick Answer XMax Inc. reported Cash and Equivalents of $161.9 thousand for fiscal year 2024. XMax Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2024 $161.9K -56.1% 2023 $369.1K -73.1% 2022 $1.37M -78.1% 2021 $6.28M -28.2% 2020 $8.74M +17.8% 2019 $7.42M +2947.9% 2018 $243.6K -95.7% 2017 $5.72M +121.1% 2016 … Read more
Quick Answer XMax Inc. reported Total Assets of $9.92 million for fiscal year 2024. XMax Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2024 $9.92M +59.0% 2023 $6.24M -45.9% 2022 $11.53M -60.9% 2021 $29.53M -36.5% 2020 $46.48M -35.0% 2019 $71.56M -20.6% 2018 $90.09M +12.8% 2017 $79.86M +3.7% 2016 $77.04M -14.2% 2015 … Read more
Quick Answer XMax Inc. reported Diluted EPS of $1.48 per share (loss) for fiscal year 2024. XMax Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2024 -$1.48 +70.2% 2023 -$4.96 +59.8% 2022 -$12.34 -171.8% 2020 -$4.54 -198.7% 2019 -$1.52 -263.4% 2018 $0.93 +564.3% 2017 $0.14 +450.0% 2016 -$0.04 -140.0% 2015 $0.10 … Read more
Quick Answer XMax Inc. reported Net Income of -$5.56 million for fiscal year 2024. XMax Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2024 -$5.56M +28.0% 2023 -$7.72M +54.8% 2022 -$17.10M +14.3% 2021 -$19.96M +23.5% 2020 -$26.08M -203.2% 2019 -$8.60M -262.3% 2018 $5.30M +40.8% 2017 $3.76M +436.7% 2016 -$1.12M -150.8% 2015 … Read more
Quick Answer XMax Inc. reported Revenue (ASC 606) of $9.69 million for fiscal year 2024. XMax Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2024 $9.69M -12.6% 2023 $11.09M -13.0% 2022 $12.74M +1.5% 2021 $12.56M — Quarterly Revenue (ASC 606) Quarter Ending Revenue (ASC 606) YoY QoQ September 30, … Read more
Quick Answer XMax Inc. reported Total Revenue of $9.69 million for fiscal year 2024. XMax Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2024 $9.69M -12.6% 2023 $11.09M -13.0% 2022 $12.74M -0.5% 2021 $12.81M +12.9% 2020 $11.35M -48.4% 2019 $21.98M -72.9% 2018 $81.18M -23.8% 2017 $106.49M +14.9% 2016 $92.65M +3.0% 2015 … Read more
Quick Answer XMax Inc. reported Total Revenue of $9.69 million for fiscal year 2024. XMax Inc. — Key Financials by Year Metric 2024 2023 2022 2021 2020 2019 Total Revenue $9.69M-12.6% $11.09M-13.0% $12.74M-0.5% $12.81M+12.9% $11.35M-48.4% $21.98M-72.9% Revenue (ASC 606) $9.69M-12.6% $11.09M-13.0% $12.74M+1.5% $12.56M — — Net Income -$5.56M+28.0% -$7.72M+54.8% -$17.10M+14.3% -$19.96M+23.5% -$26.08M-203.2% -$8.60M-262.3% Diluted EPS … Read more
Quick Answer Xilio Therapeutics, Inc. reported Shares Outstanding of 4.53 million shares for fiscal year 2025. Xilio Therapeutics, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 4.53M +38.6% 2024 3.27M -88.2% 2023 27.61M +0.7% 2022 27.43M +0.2% 2021 27.36M +3865.4% 2020 689,929 — Quarterly Shares Outstanding Quarter Ending Shares Outstanding … Read more
Quick Answer Xilio Therapeutics, Inc. reported Operating Income of -$41.98 million for fiscal year 2025. Xilio Therapeutics, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$41.98M +30.7% 2024 -$60.58M +23.4% 2023 -$79.13M +11.2% 2022 -$89.15M -18.8% 2021 -$75.04M -37.5% 2020 -$54.56M — Quarterly Operating Income Quarter Ending Operating Income YoY … Read more
Quick Answer Xilio Therapeutics, Inc. reported R&D Expense of $56.04 million for fiscal year 2025. Xilio Therapeutics, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $56.04M +36.0% 2024 $41.21M -21.0% 2023 $52.14M -11.9% 2022 $59.20M +15.7% 2021 $51.19M +16.6% 2020 $43.91M — Quarterly R&D Expense Quarter Ending R&D Expense YoY … Read more